|Primary analysis complete
|Study Start Date:
|Study Made Public:
A Phase 1 placebo-controlled study extension to HVTN 073 / SAAVI 102, to evaluate the safety and immunogenicity of Novartis Sub C gp140 vaccine with MF59 adjuvant, as a boost following SAAVI DNA-C2 vaccine and SAAVI MVA-C vaccine, in HIV uninfected healthy adult participants in South Africa and the United States
HVTN 073E (SAAVI 102 and HVTN 073 extension) is a Phase I clinical trial to evaluate the safety and immunogenicity of a Sub C gp140 vaccine with MF59 adjuvant boost given to participants who received SAAVI DNA-C2 and SAAVI MVA-C in HVTN 073.
Sign in to see full information about this study and to download study data.
ProductsProduct info coming soon!
No integrated data is available for this study.
No non-integrated data is available for this study.